Praxis Investment Management Inc. Sells 750 Shares of Teleflex Incorporated $TFX

Praxis Investment Management Inc. lowered its holdings in Teleflex Incorporated (NYSE:TFX) by 30.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,750 shares of the medical technology company’s stock after selling 750 shares during the period. Praxis Investment Management Inc.’s holdings in Teleflex were worth $207,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Thompson Investment Management Inc. raised its position in shares of Teleflex by 2.1% in the second quarter. Thompson Investment Management Inc. now owns 4,970 shares of the medical technology company’s stock valued at $588,000 after purchasing an additional 100 shares during the period. CX Institutional raised its position in shares of Teleflex by 14.7% in the second quarter. CX Institutional now owns 872 shares of the medical technology company’s stock valued at $103,000 after purchasing an additional 112 shares during the period. Signaturefd LLC raised its position in shares of Teleflex by 38.3% in the first quarter. Signaturefd LLC now owns 433 shares of the medical technology company’s stock valued at $60,000 after purchasing an additional 120 shares during the period. Empirical Finance LLC raised its position in shares of Teleflex by 7.9% in the first quarter. Empirical Finance LLC now owns 1,690 shares of the medical technology company’s stock valued at $234,000 after purchasing an additional 124 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of Teleflex by 30.2% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 556 shares of the medical technology company’s stock valued at $77,000 after purchasing an additional 129 shares during the period. Institutional investors own 95.62% of the company’s stock.

Insider Transactions at Teleflex

In related news, Director Stuart A. Randle purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 5th. The shares were purchased at an average price of $115.86 per share, with a total value of $115,860.00. Following the acquisition, the director directly owned 7,547 shares of the company’s stock, valued at approximately $874,395.42. This represents a 15.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Andrew A. Krakauer acquired 1,000 shares of the business’s stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average cost of $115.25 per share, with a total value of $115,250.00. Following the purchase, the director directly owned 7,192 shares in the company, valued at $828,878. This represents a 16.15% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 5,500 shares of company stock worth $633,590. Company insiders own 1.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on TFX. Mizuho boosted their price target on shares of Teleflex from $130.00 to $135.00 and gave the company a “neutral” rating in a research report on Friday, August 1st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Teleflex in a report on Wednesday, October 8th. Royal Bank Of Canada upped their target price on shares of Teleflex from $130.00 to $135.00 and gave the stock a “sector perform” rating in a report on Friday, August 1st. Wall Street Zen lowered shares of Teleflex from a “strong-buy” rating to a “buy” rating in a report on Monday, September 15th. Finally, Wells Fargo & Company decreased their target price on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating on the stock in a report on Friday, August 1st. One investment analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Teleflex presently has a consensus rating of “Reduce” and a consensus price target of $141.57.

Teleflex Price Performance

Shares of NYSE:TFX opened at $128.44 on Monday. The company’s fifty day moving average price is $125.09 and its 200-day moving average price is $123.52. The firm has a market capitalization of $5.68 billion, a price-to-earnings ratio of 30.22, a PEG ratio of 1.79 and a beta of 1.05. Teleflex Incorporated has a one year low of $108.90 and a one year high of $241.41. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.36 by $0.37. The firm had revenue of $780.90 million for the quarter, compared to analyst estimates of $771.53 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.42 EPS. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. On average, equities research analysts anticipate that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 15th. Stockholders of record on Friday, August 15th were issued a $0.34 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. Teleflex’s dividend payout ratio is presently 32.00%.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.